3-chloro-6-phenylpyridazine-4-carbonitrile | 94011-64-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 3-chloro-6-phenylpyridazine-4-carbonitrile
• 英文别名: 3-Chloro-4-cyano-6-phenylpyridazine；3-chloro-6-phenyl-pyridazine-4-carbonitrile
• CAS: 94011-64-0
• 化学式: C₁₁H₆ClN₃
• 分子量: 215.642
• InChiKey: NYUXYSKLVIYNMD-UHFFFAOYSA-N

物化性质

• 熔点：
  206 °C(Solv: isopropanol (67-63-0))
• 沸点：
  451.6±45.0 °C(Predicted)
• 密度：
  1.37±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  49.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-chloro-6-phenylpyridazine-4-carbonitrile 生成 巴泽若宁
  参考文献：
  名称：

  J. Med. Chem. 1989, 32, 528-537

  摘要：

  DOI：
• 作为产物：
  描述：

  diethyl phenacylmalonate 在 ammonium hydroxide 、 溴 、 一水合肼 、 三氯氧磷 作用下， 以 乙醇 、 溶剂黄146 为溶剂， 反应 3.0h， 生成 3-chloro-6-phenylpyridazine-4-carbonitrile
  参考文献：
  名称：

  3-Aminopyridazine derivatives with atypical antidepressant, serotonergic and dopaminergic activities

  摘要：

  Minaprine [3-[(beta-morpholinoethyl)amino]-4-methyl-6-phenylpyridazine dihydrochloride] is active in most animal models of depression and exhibits in vivo a dual dopaminomimetic and serotoninomimetic activity profile. In an attempt to dissociate these two effects and to characterize the responsible structural requirements, a series of 47 diversely substituted analogues of minaprine were synthesized and tested for their potential antidepressant, serotonergic, and dopaminergic activities. The structure-activity relationships show that dopaminergic and serotonergic activities can be dissociated. Serotonergic activity appears to be correlated mainly with the substituent in the 4-position of the pyridazine ring whereas the dopaminergic activity appears to be dependent on the presence, or in the formation, of a para-hydroxylated aryl ring in the 6-position of the pyridazine ring.

  DOI：

  10.1021/jm00123a004

文献信息

• Novel aryl- and heteroarylpiperazines
  申请人：——

  公开号：US20030236259A1

  公开（公告）日：2003-12-25

  Novel aryl- and heteroarylpiperazines, use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds, and a method of treatment employing these compounds and compositions. The compounds show a high and selective binding affinity to the histamine H3 receptor indicating histamine H3 receptor antagonistic, inverse agonistic or agonistic activity. As a result, the compounds are useful for the treatment of diseases and disorders related to the histamine H3 receptor.

  新颖的芳基和杂环基哌嗪类化合物，这些化合物作为药物组合物的用途，包含这些化合物的药物组合物，以及利用这些化合物和组合物的治疗方法。这些化合物显示出对组胺H3受体的高度和选择性结合亲和力，表明具有组胺H3受体拮抗、逆激动或激动活性。因此，这些化合物对于治疗与组胺H3受体相关的疾病和紊乱是有用的。
• Pyrazolo[3,4-<i>c</i>]pyridazines as Novel and Selective Inhibitors of Cyclin-Dependent Kinases
  作者：Miguel F. Braña、Mónica Cacho、M. Luisa García、Elena P. Mayoral、Berta López、Beatriz de Pascual-Teresa、Ana Ramos、Nuria Acero、Francisco Llinares、Dolores Muñoz-Mingarro、Olivier Lozach、Laurent Meijer

  DOI：10.1021/jm058013g

  日期：2005.11.1

  Pyrazolopyridazine 1a was identified in a high-throughput screening carried out by BASF Bioresearch Corp. (Worcester, MA) as a potent inhibitor of CDK1/cyclin B and shown to have selectivity for the CDK family. Analogues of the lead compound have been synthesized and their antitumor activities have been tested. A molecular model of the complex between the lead compound and the CDK2 ATP binding site

  在由BASF Bioresearch Corp.（马萨诸塞州伍斯特）进行的高通量筛选中鉴定出吡唑并哒嗪1a为有效的CDK1 / cyclin B抑制剂，并显示出对CDK家族具有选择性。已合成了铅化合物的类似物，并测试了其抗肿瘤活性。使用构象搜索和自动对接技术的组合，已建立了先导化合物和CDK2 ATP结合位点之间的复合物的分子模型。所得复合物的稳定性已通过分子动力学模拟进行了评估，并且在拟议的化合物1a结合方式的基础上，对合成的类似物所获得的实验结果进行了合理化处理。SAR研究的结果，
• Pyrazolopyridines and pyrazolopyridazines as antidabetics
  申请人：——

  公开号：US20040019052A1

  公开（公告）日：2004-01-29

  The present invention includes compound of formula (I), 1 or a derivative thereof, wherein Y is CH or N; R 1 is unsubstituted or substituted alkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted alkenyl, unsubstituted or substituted cycloalkenyl, unsubstituted or substituted aryl, aralkyl wherein the aryl and the alkyl moieties may each independently be unsubstituted or substituted, aralkenyl wherein the aryl, and alkenyl moieties may each independently be unsubstituted or substituted, unsubstituted or substituted heterocyclyl, or heterocyclylalkyl wherein the heterocyclyl and the alkyl moieties may each independently be unsubstituted or substituted; and R 2 is unsubstituted aryl or unsubstituted or substituted or substituted heteroaryl. Additionally the present invention includes a process for preparing such a compound, a pharmaceutical composition containing such a compound, and the use of such a compound in medicine.

  本发明包括式(I)的化合物或其衍生物，其中Y是CH或N；R1是未取代或取代的烷基，未取代或取代的环烷基，未取代或取代的烯基，未取代或取代的环烯基，未取代或取代的芳基，芳基烷基，其中芳基和烷基基团各自可以独立地未取代或取代，芳基烯基，其中芳基和烯基基团各自可以独立地未取代或取代，未取代或取代的杂环基，或杂环基烷基，其中杂环基和烷基基团各自可以独立地未取代或取代；以及R2是未取代的芳基或未取代或取代的杂芳基。此外，本发明还包括制备这种化合物的方法，含有这种化合物的药物组合物，以及这种化合物在医学上的用途。
• A novel route to the 5,6-dihydro-4-H-thieno[3,2-b]pyrrol-5-one ring system involving an intermediate substituted-thiophene synthesis
  作者：Shuanghua Hu、Yazhong Huang、Michael A. Poss、Robert G. Gentles

  DOI：10.1002/jhet.5570420427

  日期：2005.5

  A novel route to electron-deficient thienopyrrolones is disclosed. The target heterocycles are concisely constructed by condensation of activated α- or β-halo-substituted acrylonitriles, or ortho-substituted halo, cyano heterocycles with mercaptopyruvate, followed by reduction and subsequent lactamization.

  公开了一种缺乏电子的噻吩并吡咯烷酮的新途径。通过使活化的α-或β-卤代取代的丙烯腈或邻位取代的卤素，氰基杂环与巯基丙酮酸酯缩合，然后还原并随后进行内酰胺化，简明地构建了目标杂环。
• Pyridazine derivatives having a psychotropic action and compositions
  申请人：Sanofi

  公开号：US04565814A1

  公开（公告）日：1986-01-21

  This invention relates to pyridazine derivatives substituted in the 4-position by a cyano group having psychotropic activity. It also relates to a process for the preparation of these products and their application as medicaments. ##STR1##

  本发明涉及一种在4位被氰基取代的吡啶嗪衍生物，具有精神药物活性。它还涉及制备这些产品的过程以及它们作为药物的应用。##STR1##